Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leigh Ellis

Showing results (31-40 of 70) with videos related to

Pageof 7
Sort By:
The Prostate|May 27, 2016
Generation of a C57BL/6 MYC-Driven Mouse Model and Cell Line of Prostate CancerLeigh Ellis, ShengYu Ku, Qiuhui Li, et al.
Biorxiv : the Preprint Server for Biology|February 14, 2024
MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancerBeatriz German, Jagpreet N Singh, Marcos AdS Fonseca, et al.
The Prostate|December 12, 2019
Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy MeetingAndrea K Miyahira, Adam Sharp, Leigh Ellis, et al.
Blood|April 23, 2009
The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacyLeigh Ellis, Michael Bots, Ralph K Lindemann, et al.
Free Radical Biology & Medicine|November 17, 2010
Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cellsPiergiorgio Pettazzoni, Stefania Pizzimenti, Cristina Toaldo, et al.
Oncotargets and Therapy|September 23, 2021
Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient SelectionAlexis LeVee, Ching Ying Lin, Edwin Posadas, et al.
BMC Cancer|August 11, 2016
HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinomaSwathi Ramakrishnan, ShengYu Ku, Eric Ciamporcero, et al.
Molecular Cancer Therapeutics|May 27, 2010
Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft studyHans J Hammers, Henk M Verheul, Brenda Salumbides, et al.
Cancer Immunology Research|November 6, 2014
Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine modelsLi Shen, Anette Sundstedt, Michael Ciesielski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphomaLeigh Ellis, Yan Pan, Gordon K Smyth, et al.
Pageof 7

Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
The Prostate|May 27, 2016
Generation of a C57BL/6 MYC-Driven Mouse Model and Cell Line of Prostate CancerLeigh Ellis, ShengYu Ku, Qiuhui Li, et al.
Biorxiv : the Preprint Server for Biology|February 14, 2024
MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancerBeatriz German, Jagpreet N Singh, Marcos AdS Fonseca, et al.
The Prostate|December 12, 2019
Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy MeetingAndrea K Miyahira, Adam Sharp, Leigh Ellis, et al.
Blood|April 23, 2009
The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacyLeigh Ellis, Michael Bots, Ralph K Lindemann, et al.
Free Radical Biology & Medicine|November 17, 2010
Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cellsPiergiorgio Pettazzoni, Stefania Pizzimenti, Cristina Toaldo, et al.
Oncotargets and Therapy|September 23, 2021
Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient SelectionAlexis LeVee, Ching Ying Lin, Edwin Posadas, et al.
BMC Cancer|August 11, 2016
HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinomaSwathi Ramakrishnan, ShengYu Ku, Eric Ciamporcero, et al.
Molecular Cancer Therapeutics|May 27, 2010
Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft studyHans J Hammers, Henk M Verheul, Brenda Salumbides, et al.
Cancer Immunology Research|November 6, 2014
Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine modelsLi Shen, Anette Sundstedt, Michael Ciesielski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphomaLeigh Ellis, Yan Pan, Gordon K Smyth, et al.
Pageof 7